Recent advances in Cys-loop receptor structure and function

Nature

Volumn 440, Issue 7083, 2006, Pages 448-455

  Sine, Steven M ^a   Engel, Andrew G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DATA ACQUISITION; DISEASES; IONS; MUTAGENS;

CHEMICAL-TO-ELECTRICAL TRANSDUCTION; NEUROTRANSMITTER BINDING; POSTSYNAPTIC RECEPTORS;

NEUROLOGY;

ACETYLCHOLINE; CHOLINERGIC RECEPTOR; CYSTEINE; POSTSYNAPTIC RECEPTOR;

NERVOUS SYSTEM;

BINDING AFFINITY; BINDING SITE; CATALYSIS; CHANNEL GATING; CONGENITAL MYASTHENIC SYNDROME; CRYSTAL STRUCTURE; KINETICS; MEMBRANE POTENTIAL; MUTATION; NERVOUS SYSTEM; NEUROLOGIC DISEASE; NEUROTRANSMISSION; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 33645302360     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature04708     Document Type: Review

References (82)

1. Takeuchi, A. & Takeuchi, N. Active phase of frog's endplate potential. J. Neurophysiol. 22, 395-412 (1959).
2. Montal, M. Reconstitution of channel proteins from excitable cells in planar lipid bilayer membranes. J. Membr. Biol. 98, 101-115 (1989).
3. Unwin, N. Nicotinic acetylcholine receptor at 9 Å resolution. J. Mol. Biol. 229, 1101-1124 (1993).
4. Miyazawa, A., Fujiyoshi, Y. & Unwin, N. Nicotinic acetylcholine receptor at 4.6 Å resolution: transverse tunnels in the channel wall. J. Mol. Biol. 288, 765-786 (1999).
5. Smit, A. B. et al. A glia-derived acetylcholine-binding protein that modulates synaptic transmission. Nature 411, 261-268 (2001).
6. Brejc, K. et al. Crystal structure of ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. Nature 411, 269-276 (2001).
7. Sine, S. M., Wang, H.-L. & Bren, N. Lysine scanning mutagenesis delineates structure of nicotinic receptor binding domain. J. Biol. Chem. 277, 29210-29223 (2002).
8. 2+-binding sites. Proc. Natl Acad. Sci. USA 99, 3210-3215 (2002).
9. Molles, B. E., Tsigelny, I., Gao, S. X., Sine, S. M. & Taylor, P. Residues in the nicotinic acetylcholine receptor interact to confer selectivity of waglerin-1 for the α-ε subunit interface site. Biochemistry 41, 7895-7906 (2002).
10. Schapira, M., Abagyan, R. & Totrov, M. Structural model of nicotinic receptor isotypes bound to acetylcholine and nicotine. BMC Struct. Biol. 2, 1-8 (2002).
11. Miyazawa, A., Fujiyoshi, Y. & Unwin, N. Structure and gating mechanism of the acetylcholine receptor pore. Nature 424, 949-955 (2003).
12. Bouzat, C. et al. Coupling of agonist binding to channel gating in an ACh-binding protein linked to an ion channel. Nature 430, 896-900 (2004).
13. Law, R. J., Henchman, R. H. & McCammon, J. A. A gating mechanism proposed from a simulation of a human α7 nicotinic acetylcholine receptor. Proc. Natl Acad Sci. USA 102, 6813-6818 (2005).
14. Unwin, N. Refined structure of the nicotinic acetylcholine receptor at 4 Å resolution. J. Mol. Biol. 346, 967-989 (2005).
15. Lingle, C. J., Maconochie, D. & Steinbach, J. H. Activation of skeletal muscle nicotinic acetylcholine receptors. J. Membr. Biol. 126, 195-217 (1992).
16. Edmonds, B., Gibb, A. J. & Colquhoun, D. Mechanisms of activation of muscle nicotinic acetylcholine receptors and the time course of endplate currents. Annu. Rev. Physiol. 57, 469-493 (1995).
17. Jackson, M. B. Ligand-gated channel: potssynaptic receptors and drug targets. Adv. Neurol. 79, 511-524 (1999).
18. Sine, S. M. The nicotinic receptor ligand binding domain. J. Neurobiol. 53, 431-446 (2002).
19. Jackson, M. B. Kinetics of unliganded acetycholine receptor channel gating. Biophys. J. 49, 663-672 (1986).
20. Jackson, M. B. Perfection of a synaptic receptor: kinetics and energetics of the acetylcholine receptor. Proc. Natl Acad. Sci. USA 86, 2199-2203 (1989).
21. Ohno, K. et al. Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor ε subunit. Neuron 17, 157-170 (1996).
22. Jackson, M. B. Dependence of acetylcholine receptor kinetics on agonist concentration in cultured mouse muscle fibres. J. Physiol. (Lond.) 397, 555-583 (1988).
23. Sine, S. M., Claudio, T. & Sigworth, F. J. Activation of Torpedo acetylcholine receptors expressed in mouse fibroblasts: single-channel current kinetics reveal distinct agonist binding affinities. J. Gen. Physiol. 96, 395-437 (1990).
24. Zhang, Y., Chen, J. & Auerbach, A. Activation of recombinant mouse acetylcholine receptors by acetylcholine, carbamylcholine and tetraethylammonium. J. Physiol. (Lond.) 486, 189-206 (1995).
25. Colquhoun, D. & Sakmann, B. Fluctuations in the microsecond time range of the current through single acetylcholine receptor ion channels. Nature 294, 464-466 (1981).
26. Celie, P. H. N. et al. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron 41, 907-914 (2004).
27. Hansen, S. B. et al. Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations. EMBO J. 24, 3635-3646 (2005).
28. Zhong, W. et al. From ab initio quantum mechanics to molecular neurobiology: a cation-π binding site in the nicotinic receptor. Proc. Natl Acad. Sci. USA 95, 12088-12093 (1998).
29. Lee, W. Y. & Sine, S. M. Invariant aspartic acid in muscle nicotinic receptor contributes selectively to the kinetics of agonist binding. J. Gen. Physiol. 124, 555-567 (2004).
30. Gao, F. et al. Agonist-mediated conformational changes in acetylcholine-binding protein revealed by simulation and intrinsic tryptophan fluorescence. J. Biol. Chem. 280, 8443-8451 (2005).
31. Liu, Y. & Dilger, J. P. Opening rate of acetylcholine receptor channels. Biophys. J. 60, 424-432 (1991).
32. Maconochie, D. & Steinbach, J. H. The channel opening rate of adult- and fetal-type mouse muscle nicotinic receptors activated by acetylcholine. J. Physiol. (Lond.) 506, 53-72 (1998).
33. Mukhtasimova, F., Free, C. & Sine, S. M. Initial coupling of binding to gating mediated by conserved residues in muscle nicotinic receptor. J. Gen. Physiol. 506, 53-72 (2005).
34. A receptor. Nature 421, 272-275 (2003).
35. Chakrapani, S., Bailey, T. D. & Auerbach, A. Gating dynamics of the acetylcholine receptor extracellular domain. J. Gen. Physiol. 123, 341-356 (2004).
36. Xiu, X., Hanek, A. P., Wang, J., Lester, H. A. & Dougherty, D. A. A unified view of the role of electrostatic interactions in modulating the gating of Cys loop receptors. J. Biol. Chem. 280, 41655-41666 (2005).
37. Lyford, L. K., Sproul, A. D., Eddins, D., McLaughlin, J. T. & Rosenberg, R. L. Agonist-induced conformational changes in the extracellular domain of α7 nicotinic acetylcholine receptors. Mol. Pharmacol. 64, 650-658 (2003).
38. Schofield, C. M., Jenkins, A. & Harrison, N. L. A highly conserved aspartic acid residue in the signature disulfide loop of the α1 subunit is a determinant of gating in the glycine receptor. J. Biol. Chem. 278, 34079-34083 (2003).
39. Absalom, N. L., Lewis, T. M., Kaplan, W., Pierce, K. D. & Schofield, P. R. Role of charged residues in coupling ligand binding and channel activation in the extracellular domain of the glycine receptor. J. Biol. Chem. 278, 50151-50157 (2003).
40. Sala, F., Mulet, J., Sala, S., Gerber, S. & Criado, M. Charged amino acids of the N-terminal domain are involved in coupling binding and gating in α7 nicotinic receptors. J. Biol. Chem. 280, 6642-6647 (2005).
41. Le Novère, N. & Changeux, J.-P. The Ligand-Gated Ion Channel database: an example of a sequence database in neuroscience. Phil. Trans. R. Soc. Lond B 356, 1121-1130 (2001).
42. Lee, W. Y. & Sine, S. M. Principal pathway coupling agonist binding to channel gating in nicotinic receptors. Nature 438, 243-247 (2005).
43. Serrano, L., Horovitz, A., Avron, B., Bycroft, M. & Fersht, A. Estimating the contribution of engineered surface electrostatic interactions to protein stability by using double-mutant cycles. Biochemistry 29, 9343-9352 (1990).
44. Vaughan, C. K., Harryson, P., Buckel, A. M. & Fersht, A. R. A structural double-mutant cycle: estimating the strength of a buried salt bridge in barnase. Acta Crystallogr. D 58, 591-600 (2002).
45. Lummis, S. C. R. et al. Cis-trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel. Nature 438, 248-252 (2005).
46. Imoto, K. et al. Rings of negatively charged amino acids determine the acetylcholine receptor channel conductance. Nature 335, 645-648 (1988).
47. 3 receptors. Nature 424, 321-324 (2003).
48. Unwin, N. Acetylcholine receptor channel imaged in the open state. Nature 373, 37-43 (1995).
49. Wilson, G. G. & Karlin, A. The location of the gate in the acetylcholine receptor channel. Neuron 20, 1269-1281 (1998).
50. Taly, A. et al. Normal mode analysis suggests a quaternary twist model for the nicotinic receptor gating mechanism. Biophys. J. 88, 3954-3965 (2005).
51. Paas, Y. et al. Pore conformations and gating mechanism of a Cys-loop receptor. Proc. Natl Acad. Sci. USA 102, 15877-15882 (2005).
52. Cymes, G. D., Ni, Y. & Grosman, C. Probing ion-channel pores one proton at a time. Nature 438, 975-980 (2005).
53. Fersht, A. R., Leatherbarrow, R. J. & Wells, T. N. C. Structure-activity relationships in engineered proteins: analysis of use of binding energy by linear free-energy relationships. Biochemistry 26, 630-638 (1987).
54. Grosman, C., Zhou, M. & Auerbach, A. Mapping the conformational wave of acetylcholine receptor channel gating. Nature 403, 773-776 (2002).
55. Cymes, G. D., Grosman, C. & Auerbach, A. Structure of the transition state of gating in the acetylcholine receptor channel pore: a Φ-value analysis. Biochemistry 41, 5548-5555 (2002).
56. Chakrapani, S., Bailey, T. D. & Auerbach, A. The role of loop 5 in acetylcholine receptor channel gating. J. Gen. Physiol. 122, 521-539 (2003).
57. Auerbach, A. Gating of acetylcholine receptor channels: brownian motion across a broad transition state. Proc. Natl Acad. Sci. USA 102, 1408-1412 (2005).
58. Zhou, Y., Pearson, J. E. & Auerbach, A. Φ-value analysis of a linear, sequential reaction mechanism: theory and application to channel gating. Biophys. J. 89, 3680-3685 (2005).
59. Engel, A. G., Ohno, K. & Sine, S. M. Sleuthing molecular targets for neurological diseases at the neuromuscular junction. Nature Rev. Neurosci. 4, 339-352 (2003).
60. Steinlein, O. K. Genetic mechanisms that underlie epilepsy. Nature Rev. Neurosci. 5, 400-408 (2004).
61. Shiang, R. et al. Mutational analysis of familial and sporadic hyperekplexia. Ann. Neurol. 38, 85-91 (1995).
62. Beeson, D., Hantai, D., Lochmuller, H. & Engel, A. G. 126th International Workshop: congenital myasthenic syndromes. Neuromuscul. Disord. 15, 498-512 (2005).
63. Engel, A. G. & Sine, S. M. Current understanding of congenital myasthenic syndromes. Curr. Opin. Pharmacol. 5, 306-321 (2005).
64. Ohno, K., Brengman, J. M., Tsujino, A. & Engel, A. G. Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme. Proc. Natl Acad. Sci. USA 95, 9654-9659 (1998).
65. Ohno, K. et al. Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc. Natl Acad. Sci. USA 98, 2017-2022 (2001).
66. Ohno, K. et al. Rapsyn mutations in humans cause endplate acetylcholine receptor deficiency and myasthenic syndrome. Am. J. Hum. Genet. 70, 875-885 (2002).
67. Chevessier, F. et al. MUSK, a new target for mutations causing congenital myasthenic syndrome. Hum. Mol. Genet. 13, 3229-3240 (2004).
68. Tsujino, A. et al. Myasthenic syndrome caused by mutation of the SCN4A sodium channel. Proc. Natl Acad. Sci. USA 100, 7377-7382 (2003).
69. Ohno, K. et al. Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor ε subunit gene: identification and functional characterization of six new mutations. Hum. Mol. Genet. 6, 753-766 (1997).
70. Fukudome, T., Ohno, K., Brengman, J. M. & Engel, A. G. Quinidine normalizes the open duration of slow-channel mutants of the acetylcholine receptor. Neuroreport 9, 1907-1911 (1998).
71. Harper, C. M. & Engel, A. G. Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome. Ann. Neurol. 43, 480-484 (1998).
72. Harper, C. M., Fukudome, T. & Engel, A. G. Treatment of slow channel congenital myasthenic syndrome with fluoxetine. Neurology 60, 170-173 (2003).
73. Ohno, K. et al. Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the ε subunit. Proc. Natl Acad. Sci. USA 92, 758-762 (1995).
74. Milone, M. et al. Slow-channel syndrome caused by enhanced activation, desensitization, and agonist binding affinity due to mutation in the M2 domain of the acetylcholine receptor α subunit. J. Neurosci. 17, 5651-5665 (1997).
75. Engel, A. G. et al. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum. Mol. Genet. 5, 1217-1227 (1996).
76. Sine, S. M. et al. Naturally occurring mutations at the acetylcholine receptor binding site independently alter ACh binding and channel gating. J. Gen. Physiol. 120, 483-496 (2002).
77. Sine, S. M. et al. Mutation of the acetylcholine receptor α subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron 15, 229-239 (1995).
78. Wang, H.-L. et al. Mutation in the M1 domain of the acetylcholine receptor α subunit decreases the rate of agonist dissociation. J. Gen. Physiol. 109, 757-766 (1997).
79. Shen, X.-M. et al. Mutation causing severe myasthenia reveals functional asymmetry of AChR signature Cys-loops in agonist binding and gating. J. Clin. Invest. 111, 497-505 (2003).
80. Shelley, C. & Colquhoun, D. A human congenital myasthenia-causing mutation (εL78P) of the muscle nicotinic acetylcholine receptor with unusual single channel properties. J. Physiol. (Lond.) 564, 377-396 (2005).
81. Hatton, C. J., Shelley, C., Brydson, M., Beeson, D. & Colquhoun, D. Properties of the human muscle nicotinic receptor, and of the slow-channel myasthenic syndrome mutant εL221F, inferred from maximum likelihood fits. J. Physiol. (Lond.) 547, 729-760 (2003).
82. Wang, H.-L. et al. Acetylcholine receptor M3 domain: stereochemical and volume contributions to channel gating. Nature Neurosci. 2, 226-233 (1999).